# Pfizer

> Pfizer is a VC fund in New York backing Biotechnology and Health Care. See 56 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 56
- Last investment: May 2026
- Lead investor: 43%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/pfizer
- X (Twitter): http://twitter.com/pfizer
- Website: http://www.pfizer.com
- Facebook: http://www.facebook.com/pfizer

Pfizer is a VC fund in New York focused on Biotechnology and Health Care. Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.

## Contacts

5 contacts available for Pfizer. Shizune tracks 22 team members at Pfizer. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/pfizer?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $800k–$11M |
| Series A | $4.5M–$412M |
| Post-IPO Equity | $25M–$320M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 34 | 61% |
| Health Care | 26 | 46% |
| Pharmaceutical | 18 | 32% |
| Therapeutics | 14 | 25% |
| Medical | 13 | 23% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 9 | 16% |
| Post-IPO Equity | 9 | 16% |
| Seed | 6 | 11% |
| Series B | 6 | 11% |
| Corporate Round | 6 | 11% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 26 | 46% |
| Israel | 5 | 9% |
| France | 2 | 4% |
| Belgium | 2 | 4% |
| Switzerland | 2 | 4% |

12 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alessandra Leone | Global CMC Sr. Manager | 0 | https://shizune.co/investors/profile/alessandra-leone |
| Angela L Coral | Senior Manager, Partnerships & Impact Reporting, Global Health & Social Impact | 0 | https://shizune.co/investors/profile/angela-l-coral |
| Barbara Dalton | Senior Managing Partner, Pfizer Ventures; VP, Worldwide Business Development | 9 | https://shizune.co/investors/profile/barbara-dalton |
| Chris Boshoff | CSO | 1 | https://shizune.co/investors/profile/chris-boshoff |
| Chris O’Donnell | Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation | 4 | https://shizune.co/investors/profile/chris-o-donnell |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CellCentric | CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $220M | Series D | May 06, 2026 |  |
| RNT Health Insights | RNT Health Insights developing an AI-assisted tool to aid endoscopists in the real-time detection of upper gastrointestinal lesions. |  | Pre-Seed | Dec 30, 2024 |  |
| RNT Health Insights | RNT Health Insights developing an AI-assisted tool to aid endoscopists in the real-time detection of upper gastrointestinal lesions. |  | Grant | Nov 11, 2024 |  |
| Promise Bio | Promise Bio develops a virtual AI platform that helps to identify multiple Post-Translational Modifications in proteins from a single blood sample. It helps to cure chronic diseases. | $8.3M | Seed | Oct 23, 2024 |  |
| CytoReason | CytoReason is a tech company developing a computational model of the human body. The company collects proprietary data from pharma companies and uses it to simulate human diseases – tissue by tissue, cell by cell. With CytoReason’s massive database and AI-led platform, pharma and biotech companies identify new opportunities, shorten trial phases,reduce development costs and increase the likelihood of approval. To date, six of the world’s top ten pharma companies use CytoReason’s technology. | $80M | Series B | Jul 17, 2024 |  |
| EvolveImmune Therapeutics | EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases. | $37.4M | Venture - Series Unknown | Nov 16, 2023 |  |
| AgomAb Therapeutics | AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases. | $100.8M | Series C | Oct 11, 2023 |  |
| CellCentric | CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $25M | Corporate Round | Jul 11, 2023 |  |
| Caribou Biosciences | Caribou Biosciences is a operator of a medical technology company intended to analyze cell and genome engineering. The company specializes in cellular engineering and analysis based on the CRISPR-Cas9 technology platform which paired with a guide RNA, cuts double-stranded DNA and allows for specific changes to DNA, enabling development oftherapeutics for agricultural biotechnology, industrial biotechnology and basic and applied biological research. | $25M | Post-IPO Equity | Jun 29, 2023 |  |
| Vedanta Biosciences | Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $106.5M | Series E | Apr 25, 2023 |  |

10 of 56 investments shown.

## Co-investors
- [Takeda Ventures](https://shizune.co/investors/profile/takeda-ventures) — VC Fund, 5 deals together
- [Canaan Partners](https://shizune.co/investors/profile/canaan-partners) — VC Fund, 4 deals together
- [Pfizer Venture Investments](https://shizune.co/investors/profile/pfizer-venture-investments) — VC Fund, 4 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 3 deals together
- [Bay City Capital](https://shizune.co/investors/profile/bay-city-capital) — VC Fund, 3 deals together
- [Elm Street Ventures](https://shizune.co/investors/profile/elm-street-ventures) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [54 Collective](https://shizune.co/investors/profile/founders-factory-africa) — VC Fund
- [Musha Ventures](https://shizune.co/investors/profile/musha-ventures) — VC Fund

## Featured in investor lists
- [Biotech VC Funds in Israel](https://shizune.co/investors/biotech-vc-funds-israel)
- [Life Science Investors in Middle East](https://shizune.co/investors/life-science-investors-middle-east)
- [Life Science VC Funds in Middle East](https://shizune.co/investors/life-science-vc-funds-middle-east)
- [Wellness Investors in Africa](https://shizune.co/investors/wellness-investors-africa)
- [Wellness VC Funds in Africa](https://shizune.co/investors/wellness-vc-funds-africa)
- [Mobile VC Funds in Kenya](https://shizune.co/investors/mobile-vc-funds-kenya)

## FAQ

### What does Pfizer invest in?

Pfizer invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Post-IPO Equity stage. Most of the 56 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Pfizer's check size?

Pfizer typically joins rounds of $800k–$11M at Seed, $4.5M–$412M at Series A and $25M–$320M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pfizer participates in.

### How do I contact Pfizer?

Public channels for Pfizer include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Pfizer?

The team at Pfizer includes Alessandra Leone (Global CMC Sr. Manager), Angela L Coral (Senior Manager, Partnerships & Impact Reporting, Global Health & Social Impact) and Barbara Dalton (Senior Managing Partner, Pfizer Ventures; VP, Worldwide Business Development), among 22 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co